GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GreenLight Biosciences Holdings PBC (NAS:GRNA) » Definitions » Equity-to-Asset

GreenLight Biosciences Holdings PBC (GreenLight Biosciences Holdings PBC) Equity-to-Asset : 0.19 (As of Mar. 2023)


View and export this data going back to 2022. Start your Free Trial

What is GreenLight Biosciences Holdings PBC Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. GreenLight Biosciences Holdings PBC's Total Stockholders Equity for the quarter that ended in Mar. 2023 was $21.94 Mil. GreenLight Biosciences Holdings PBC's Total Assets for the quarter that ended in Mar. 2023 was $113.69 Mil. Therefore, GreenLight Biosciences Holdings PBC's Equity to Asset Ratio for the quarter that ended in Mar. 2023 was 0.19.

The historical rank and industry rank for GreenLight Biosciences Holdings PBC's Equity-to-Asset or its related term are showing as below:

GRNA' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.39   Med: 0.14   Max: 0.56
Current: 0.19

During the past 4 years, the highest Equity to Asset Ratio of GreenLight Biosciences Holdings PBC was 0.56. The lowest was -3.39. And the median was 0.14.

GRNA's Equity-to-Asset is not ranked
in the Biotechnology industry.
Industry Median: 0.67 vs GRNA: 0.19

GreenLight Biosciences Holdings PBC Equity-to-Asset Historical Data

The historical data trend for GreenLight Biosciences Holdings PBC's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GreenLight Biosciences Holdings PBC Equity-to-Asset Chart

GreenLight Biosciences Holdings PBC Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Equity-to-Asset
-2.83 -1.22 -0.48 0.32

GreenLight Biosciences Holdings PBC Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 0.14 0.56 0.32 0.19

Competitive Comparison of GreenLight Biosciences Holdings PBC's Equity-to-Asset

For the Biotechnology subindustry, GreenLight Biosciences Holdings PBC's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GreenLight Biosciences Holdings PBC's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GreenLight Biosciences Holdings PBC's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where GreenLight Biosciences Holdings PBC's Equity-to-Asset falls into.



GreenLight Biosciences Holdings PBC Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

GreenLight Biosciences Holdings PBC's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Equity to Asset (A: Dec. 2022 )=Total Stockholders Equity/Total Assets
=48.062/148.598
=0.32

GreenLight Biosciences Holdings PBC's Equity to Asset Ratio for the quarter that ended in Mar. 2023 is calculated as

Equity to Asset (Q: Mar. 2023 )=Total Stockholders Equity/Total Assets
=21.936/113.689
=0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GreenLight Biosciences Holdings PBC  (NAS:GRNA) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


GreenLight Biosciences Holdings PBC Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of GreenLight Biosciences Holdings PBC's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


GreenLight Biosciences Holdings PBC (GreenLight Biosciences Holdings PBC) Business Description

Traded in Other Exchanges
N/A
Address
29 Hartwell Avenue, Lexington, MA, USA, 02421
GreenLight Biosciences Holdings PBC is a pre-commercial stage synthetic biology company with a proprietary cell-free ribonucleic acid production platform for the discovery, development, and commercialization of high-performing products to promote healthier plants, foods, and people. The company is developing RNA products for plant and life science applications to advance crop management, plant protection, animal health, vaccine development, and pandemic preparation.
Executives
Deval L Patrick other: See Remarks BAIN CAPITAL, LLC, 200 CLARENDON STREET, BOSTON MA 02116
Dennis A. Clarke other: Member of 13D group owning 10% 6 FERNWAY TERRACE, WINCHESTER MA 01890
Cummings Foundation, Inc. other: Member of 13D group owning 10% 200 WEST CUMMINGS PARK, WOBURN MA 01801
Eric Senior Anderson other: Member of 13D group owning 10% 25 N HILL ROAD, WESTOVER MA 01886
Mls Capital Fund Ii Lp other: See remarks C/O MLSC II (GP) (LABUAN) LLP, ONE MARKET ST SUITE 3525, SAN FRANCISCO CA 94105
Chelt Trading Ltd other: Member of 13D Group C/O FOX HORAN & CAMERINI LLP, 885 3RD AVENUE, 17TH FLOOR, NEW YORK NY 10022
Highview Trust other: Member of 13D Group C/O FOX HORAN & CAMERINI LLP, 885 THIRD AVENUE, 17TH FLOOR, NEW YORK NY 10022
Montealegre Lacayo Jaime Javier other: Member of 13D Group APARTADO 15-1250, ESCAZU G2
Furneaux Capital Holdco, Llc other: Member of 13D group 1 MARINA PARK DRIVE, BOSTON MA 02210
Lewis & Clark Plant Sciences Fund I, Lp other: Member of 13D group 120 S. CENTRAL AVENUE, SUITE 1000, ST. LOUIS MO 63105
Lewis & Clark Ventures I, Lp other: Member of 13D group 120 S. CENTRAL AVENUE, SUITE 1000, ST. LOUIS MO 63105
Matthew Allen Walker director, 10 percent owner C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC, 200 BOSTON AVENUE, SUITE 3100, MEDFORD MA 02155
Martha Schlicher director C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC, 200 BOSTON AVENUE, SUITE 3100, MEDFORD MA 02155
Marta Ortega-valle other: Member of 10% owner group C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC, 200 BOSTON AVENUE, SUITE 3100, MEDFORD MA 02155
Builders Vision, Llc 10 percent owner 110 NW 2ND STREET SUITE 300, BENTONVILLE AR 72712

GreenLight Biosciences Holdings PBC (GreenLight Biosciences Holdings PBC) Headlines